✦ LIBER ✦

TSH-Controlled l -Thyroxine Therapy Reduces Cholesterol Levels and Clinical Symptoms in Subclinical Hypothyroidism: A Double Blind, Placebo-Controlled Trial (Basel Thyroid Study)

✍ Scribed by Meier, Christian; Staub, Jean-Jacques; Roth, Carl-Bénédict; Guglielmetti, Merih; Kunz, Maya; Miserez, André R.; Drewe, Jürgen; Huber, Peter; Herzog, Richard; Müller, Beat

Book ID: 127145884
Publisher: Endocrine Society
Year: 2001
Tongue: English
Weight: 174 KB
Volume: 86
Category: Article
ISSN: 0021-972X
DOI: 10.1210/jcem.86.10.7973

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

TSH-Controlled L-Thyroxine Therapy Reduc

TSH-Controlled L-Thyroxine Therapy Reduces Cholesterol Levels and Clinical Symptoms in Subclinical Hypothyroidism: A Double Blind, Placebo-Controlled Trial (Basel Thyroid Study)

✍ Meier, C. 📂 Article 📅 2001 🏛 Endocrine Society 🌐 English ⚖ 170 KB

Clinical trial: a multistrain probiotic

Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study

✍ E. A. WILLIAMS; J. STIMPSON; D. WANG; S. PLUMMER; I. GARAIOVA; M. E. BARKER; B. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

Clinical trial: renzapride therapy for c

Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome – multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting

✍ A. M. GEORGE; N. L. MEYERS; R. I. HICKLING 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 160 KB

Effect of Ruxolitinib Therapy on Myelofi

Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial

✍ Mesa, R. A.; Gotlib, J.; Gupta, V.; Catalano, J. V.; Deininger, M. W.; Shields, 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 231 KB

Clinical trial: maintenance intermittent

Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease – a double-blind, placebo-controlled, randomized study

✍ R. FASS; B. DELEMOS; L. NAZARENO; R. KAO; J. XIANG; Y. LU 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 253 KB